Athenx announces major expansion, creating 1,400 jobs in Western New York
Athenex to invest $1.62 billion in drug discovery and advanced manufacturing partnership, creating 900 jobs in Dunkirk and 500 jobs in Buffalo during the next 10 years.
Governor Andrew M. Cuomo has announced a major expansion of Athenex (formerly Kinex) that will create 1,400 jobs throughout Western New York. This announcement, made possible by a partnership with the SUNY Polytechnic Institute, includes a major expansion of Athenex’s North American headquarters at the Conventus Building in Buffalo, as well as the creation of a state-of-the-art, 300,000 sq ft manufacturing facility in Dunkirk. The combined projects are expected to yield a $1.62 billion investment over 10 years from Athenex, along with $225 million from New York State.
“Western New York’s economic transformation has captured the attention of companies and investors around the globe,” said Governor Cuomo. “The business development environment in and around Buffalo has made it clear to cutting-edge companies that this is the right place to put down roots and thrive. Whether it’s pharma-based development, medical research, clean technology or advanced manufacturing, this region is defined by incredible opportunities and potential for growth. I am proud to congratulate Athenex — which could have gone anywhere — on beginning this exciting new chapter, creating good-paying jobs and further strengthening the region’s and state’s economy.”
Athenex was founded at the University of Buffalo and expanded in 2003 with a 10-year funding stream committed by more than 100 local business and medical leaders in upstate New York.
Dr Johnson Lau, Athenex CEO and Chairman said: “We have been incredibly impressed by Governor Cuomo’s leadership to attract significant new jobs within New York State. His commitment to economic development has successfully permeated an impressive ‘Open for Business’ culture we have not seen anywhere else. We also want to thank Dr Alain Kaloyeros at SUNY Polytechnic Institute. This collective leadership in New York is accelerating the transformation of the State’s economy into a global leader of next generation manufacturing across many industries. With this partnership, millions of cancer patients around the world will benefit from the oncology drugs made in New York.”
Dr Alain E. Kaloyeros, founding president and CEO of SUNY Polytechnic Institute, said: “This one-two punch for Buffalo and Western New York by an established and respected home-grown company like Athenex is another clear sign that Governor Andrew Cuomo’s innovation-driven economic development strategy is powering job creation and revitalization across Upstate New York. For a company that already operates around the world to make the business decision to grow in New York speaks volumes about what Governor Cuomo has built. The workforce, attitude, and momentum in Buffalo and across Upstate has New York competing — and winning — on a global scale.”
Howard Zemsky, President, CEO and Commissioner, Empire State Development said: “This significant expansion by Athenex, through a combined state and private investment, not only reinforces the dynamic business climate that has taken hold in Buffalo and Western New York, but it validates Governor Cuomo’s vision for the creation and development of a local economy that attracts outside business interests and, in the case of Athenex, keeps a homegrown company in the community that fostered its initial development. This is a perfect example of the Governor’s determination to support business development in our region through unique public/private partnerships that will provide cutting-edge, good-paying jobs that are sustainable.”
Athenex will invest a minimum of $1.62 billion in Western New York over the next 10 years in labour, materials and supplies. 1,400 new direct and indirect jobs (500 jobs in Buffalo and 900 in Dunkirk) will be created in areas such as high-tech manufacturing, product formulation, regulatory, pharmacovigilance, headquarter staff and suppliers and providers of service to the company. New York State, through the SUNY Polytechnic Institute, will invest a total of $225 million in the Buffalo and Dunkirk locations. Specifically
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance